Abstract
This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Astrocytoma / drug therapy
-
Astrocytoma / radiotherapy
-
Combined Modality Therapy
-
Etoposide / administration & dosage
-
Female
-
Glioblastoma / drug therapy
-
Glioblastoma / radiotherapy
-
Glioma / drug therapy*
-
Glioma / radiotherapy*
-
Humans
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Procarbazine / administration & dosage
-
Prognosis
-
Survival Analysis
-
Vincristine / administration & dosage
Substances
-
Procarbazine
-
Vincristine
-
Etoposide